相关实验视频

Updated: Jul 1, 2025

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

勒维体病中的胆固醇变化:对表现,进展和亚型的影响

Niels Okkels^1,2, Michel J Grothe^3,4,5, John-Paul Taylor⁶

¹Department of Neurology, Aarhus University Hospital, 8200 Aarhus N, Denmark.

Brain : a journal of neurology

|March 4, 2024

概括

胆性退化在勒维体疾病中很普遍,影响大脑和外周器官. 这些变化因疾病阶段和痴呆症的存在而异,为疾病进展和阿尔茨海默病的共同病理学提供了洞察力.

科学领域:

神经科学是一个神经科学.
神经学神经学
病理学病理学病理学

背景情况:

胆固醇系统功能障碍是勒维体疾病 (LBD) 的标志,包括帕金森病 (PD),勒维体痴呆症 (DLB) 和REM睡眠行为障碍 (RBD).
之前的研究集中在中枢神经系统 (CNS) 胆性改变在LBD.
新出现的证据表明,在LBD中出现了外周胆固醇化.

研究的目的:

综合中央和外围发现,全面审查LBD中的胆变化.
探索不同LBD亚型和疾病阶段的胆固醇变化的连续性.
为了研究阿尔茨海默氏症的共同病理对LBD中胆固醇退行变化的影响.

主要方法:

对LBD中胆性变化的现有文献进行系统审查.
分析受胆性消毒影响的大脑区域和外周器官.
与痴呆症和没有痴呆症的LBD中胆固醇变化的比较,以及伴随性阿尔茨海默病的胆固醇变化.

主要成果:

胆固醇功能障碍在DLB大脑区域与非痴呆LBD相比可比或更大.
后面的基础前脑胆固醇区域受到早期影响;前脑区域较晚.
在隔离的RBD中观察到腹部器官的外周胆性化,这表明早期的前性参与.

结论:

在LBD中,胆性退行遵循特定的地形模式,可能表明疾病的进展.
阿尔茨海默氏症的共同病理显著影响LBD中的胆性退化模式.
在RBD的外周胆固醇变化突出其在早期LBD病原体中的作用,并提供治疗点.

关键词:

它们是VAChT蛋白质.乙烯基胆化酶的使用胆固醇神经元是一种神经元.定子发射断层扫描 (PET).单光子发射计算机断层扫描

更多相关视频

Technique for Intranasal Administration of α-Synuclein Aggregates

Technique for Intranasal Administration of α-Synuclein Aggregates

Published on: November 8, 2024

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking

Published on: September 26, 2019

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...